Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis

Pierre-André Jarrot, MD, Laurent Chiche, MD, PhD, Baptiste Hervier, MD, PhD, Laurent Daniel, MD, PhD, Vincent Vuiblet, MD, Nathalie Bardin, PharmD, PhD, Daniel Bertin, PharmD, PhD, Benjamin Terrier, MD, PhD, Zahir Amoura, MD, PhD, Emmanuel Andrès, MD, PhD, Eric Rondeau, MD, PhD, Mohamed Hamidou, MD, Jean-Loup Pennafort, MD, Philippe Hafsan, MD, PhD, Eric Daugas, MD, PhD, Bertrand Dussol, MD, PhD, Xavier Puéchal, MD, PhD, Gilles Kaplanski, MD, PhD, and Noémie Jourde-Chiche, MD, PhD

Abstract: The aim of the study was to report the clinical, biological, and pathological characteristics of patients with glomerulonephritis (GN) secondary to systemic lupus erythematosus (SLE)/antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) overlap syndrome. A nationwide survey was conducted to identify cases of SLE/AAV overlap syndrome. Data were collected from SLE and AAV French research groups. Inclusion criteria were diagnosis of both SLE and AAV according to international classification criteria and biopsy-proven GN between 1995 and 2014. Additional cases were identified through a systematic literature review. A cohort of consecutive biopsy-proven GN was used to study the prevalence of overlapping antibodies and/or overlap syndrome.

The national survey identified 8 cases of SLE/AAV overlap syndrome. All patients were female; median age was 40 years. AAV occurred before SLE (n = 3), after (n = 3), or concomitantly (n = 2). Six patients had rapidly progressive GN and 3/8 had alveolar hemorrhage. All patients had anti-nuclear antibodies (ANA); 7/8 had p-ANCA antmyeloperoxidase (MPO) antibodies. Renal biopsies showed lupus nephritis (LN) or pauci-immune GN. Remission was obtained in 4/8 patients. A literature review identified 31 additional cases with a similarly severe presentation. In the GN cohort, ANCA positivity was found in 30% of LN, ANA positivity in 52% of pauci-immune GN, with no correlation with pathological findings. The estimated prevalence for SLE/AAV overlap syndrome was 2/101 (2%).

In patients with GN, SLE/AAV overlap syndrome may occur but with a low prevalence. Most patients have an aggressive renal presentation, with usually both ANA and anti-MPO antibodies. Further studies are needed to assess shared pathogenesis and therapeutic options.

(Received: December 8, 2015; revised: April 25, 2016; accepted: April 30, 2016)

Editor: Worawit Louthrenoo.

From the Department of Internal Medicine and Clinical Immunology (PAJ, GK), AP-HM Hôpital de La Conception; Institut UMR-S 1076 Vascular Research Center of Marseille (PAJ, GK, NJ-C), Aix-Marseille Université; Department of Internal Medicine (LC, PH), Hôpital Européen de Marseille, Marseille; Reference Center for Systemic Lupus Erythematosus (BH, ZA), Department of Internal Medicine, AP-HP Hôpital Pitié-Salpêtrière, Paris; Department of Pathology (LD), AP-HM Hôpital de La Timone, Aix-Marseille Université; Department of Pathology (VV), Paul Boin Laboratory, Reims, France; Laboratory of Immunology (NB, DB), AP-HM Hôpital de la Conception, Aix-Marseille Université, Marseille; French Vasculitis Study Group (BT, XP), Department of Internal Medicine, National Reference Center for Necrotizing Vasculitis, AP-HP Hôpital Cochin, University Paris-Descartes; Department of Internal Medicine (EA), Hôpital Civil, Strasbourg; Department of Nephrology (ER), AP-HP Hôpital Tenon, Paris; Department of Internal Medicine (MH), Hôpital Hôtel-Dieu, Nantes; Department of Internal Medicine (J-LP), Hôpital Robert Debré, Reims Université, Reims; Groupe Coopératif sur le Lupus Rénal (ED), Department of Nephrology, AP-HP Hôpital Bichat, Paris; and Department of Nephrology (BD, NJ-C), AP-HM Hôpital Conception, Aix-Marseille Université, Marseille, France.

Correspondence: Noémie Jourde-Chiche, Aix-Marseille Université, Department of Nephrology, AP-HM, Hôpital de La Conception, Marseille, France (e-mail: noemie.jourde@ap-hm.fr).

The authors have no funding and conflicts of interest to disclose. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abbreviations: AAV = ANCA-associated vasculitis, ANA = antinuclear antibodies, ANCA = antineutrophil cytoplasmic antibodies, AZA = azathioprine, BVAS = Birmingham vasculitis activity score, c-ANCA = cytoplasmic ANCA, CAPS = catastrophic antiphospholipid syndrome, CGN = crescentic glomerulonephritis, CKD = chronic kidney disease, CR = complete remission, CS = corticosteroids, CYC = cyclophosphamide, dDNA = double-stranded DNA, GN = glomerulonephritis, HCQ = hydroxychloroquine, IAH = intra-alveolar hemorrhage, IIF = indirect immunofluorescence, LN = lupus nephritis, MMF = mycophenolate mofetil, MPO = myeloperoxidase, p-ANCA = perinuclear ANCA, PE = plasma exchange, PR = partial remission, PR3 = proteinase 3, RPGN = rapidly progressive glomerulonephritis, RTX = rituximab, SLE = systemic lupus erythematosus, SLEDAI = SLE disease activity index.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic and severe autoimmune disease characterized by the presence of a wide range of serum autoantibodies, such as antinuclear (ANA) and antidouble-stranded deoxyribonucleic acid (anti-dsDNA) antibodies.1 SLE’s clinical presentation is heterogeneous and can display a broad spectrum of manifestations, including lupus nephritis (LN) in 30% to 60% of patients and vasculitis in 11% of patients.2–4 LN is characterized by glomerular immune-complex deposits.5 In contrast, renal involvement of...
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is typically a pauci-immune crescentic glomerulonephritis (GN).6 Crescent formation, which is the hallmark of renal vasculitis, is however frequently encountered in severe forms of LN.7 In addition, ANCA are found in up to 20% of SLE patients, although their pathogenic role in the formation of crescents or necrotizing vasculitis remains unclear.8 Some patients fulfilling both SLE and AAV classification criteria were recently defined as having SLE/AAV overlap syndrome.9 However, renal pathological details were often unavailable in these cases.

The aims of this study were (i) to describe SLE/AAV overlap cases with biopsy proven GN, and (ii) to assess the prevalence of overlapping autoantibodies and SLE/AAV overlap syndrome in an independent cohort of patients with biopsy-proven GN.

METHODS

Ethical Statement

This retrospective observational study was conducted according to the principles expressed in the Declaration of Helsinki. The nationwide survey was conducted though the registries of French reference centers approved by the “Commission Nationale de l’Informatique et des Libertés” (CNIL, registration number 1884512). The cohort analysis was conducted through a biobank approved by the French government (Cellule de Bioéthique, Ministère de l’Enseignement Supérieur et de la Recherche). All patients included in this biobank (DC-2012-1704) gave their written informed consent prior to the collection of data and of samples.

Nationwide Survey

A retrospective nationwide survey was conducted to collect cases of SLE/AAV overlap syndrome with biopsy-proven GN, diagnosed between 1995 and 2014, through the databases of the “French Vasculitis Study Group” (FVSG), the “Club Rhumatismes et Inflammation” (CRI), and the “Groupe Coopératif sur le Lupus Rénal” (GCLR). Medical charts were reviewed independently by 2 experts to validate the diagnosis of overlap syndrome. Inclusion criteria were as follows: adult or pediatric patients fulfilling (successively or concomitantly) both the American College of Rheumatology (ACR) 1997 SLE classification criteria10 and the revised Chapel Hill 2012 AAV definition criteria,11 associated with biopsy-proven LN or pauci-immune GN. Exclusion criteria were having positive ANCA, ANA, anti-dsDNA, anti-MPO, anti-PR3.

Clinical manifestations of the initial disease (SLE, AAV, or inaugural overlap syndrome), as well as at the time when overlap syndrome was diagnosed, were recorded: general symptoms (fever, weight loss); cutaneous lesions; ear–nose–throat involvement: ophthalmologic, articular, neurologic, cardiac, pulmonary, vascular involvement. Disease activity at the time when overlap syndrome was diagnosed was assessed by both the SLE Disease Activity Index (SLEDAI)12 and the Birmingham Vasculitis Activity Score (BVAS).13 Laboratory results were recorded at the time when overlap syndrome was diagnosed: blood leukocyte count, platelet count, hemoglobin, markers of hemolysis, Coombs test, C-reactive protein, serum creatinine, 24-h proteinuria and urinary sediment, ANA, antinuclear antibodies, anti-dsDNA, antiphospholipid antibodies (anticardiolipin, anti-β2GP1, and/or lupus anticoagulant), C3 and C4 complement fractions. Results of the kidney biopsy performed at the time when overlap syndrome was diagnosed included findings from light microscopy and immunofluorescence (IF). LN was classified according to the 2003 revised classification of ISN/RPS.5 Pauci-immune GN was classified according to the 2010 classification.6 The percentages of sclerotic and crescentic glomeruli and the presence of endocapillary proliferation were detailed for each biopsy. The presence of subendothelial, mesangial, and subepithelial immune complex deposits (IgG, IgM, IgA, C3, or C1q) were semiquantitatively assessed as (−), (±), +, 2+, 3+, 4+. The therapeutic regimen used to treat the initial disease and overlap syndrome was also recorded. Response to treatment was evaluated at M6, M12, M18, and M24 after overlap syndrome was diagnosed according to the remission criteria for the most recent disease, as detailed in the Supplemental Methods Appendix, http://links.lww.com/MD/A993.

Literature Review

Clinical, biological, and pathological characteristics of the patients identified through the national survey were compared with cases of SLE/AAV overlap syndrome. These were identified through a systematic literature review using the following MESH terms within MEDLINE (National Library of Medicine, Bethesda, MD): systemic vasculitis, AAV, SLE, LN, ANCA, Wegener’s granulomatosis, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), overlap, and association.

Cohort Analysis and Estimated Prevalence

The prevalence of overlapping antibodies and/or SLE/AAV overlap syndrome was assessed in an independent cohort of consecutive patients with LN or pauci-immune GN diagnosed between 2005 and 2014. Inclusion criteria were being an adult or pediatric patient with biopsy-proven LN or pauci-immune GN and with available immunological data (ANA, anti-dsDNA, ANCA, Indirect IF [IIF], anti-MPO, anti-PR3). Exclusion criteria were similar to those of the nationwide survey. Pathological and immunological analytical methods are detailed in the Supplemental Methods Appendix, http://links.lww.com/MD/A993.

Statistics

Statistical software GraphPad Prism (GraphPad software, San Diego, CA) was used for the analyses. For the descriptive analyses, results were expressed as frequencies and percentages of categorical variables. Means and standard deviations or medians and ranges were used for continuous variables with asymmetrical distributions. The groups of patients with GN with/without overlapping antibodies were compared using the chi-squared test for frequencies and Student’s t test for continuous variables. Statistical significance was considered at $P < 0.05$.

RESULTS

 Nationwide Survey

The nationwide survey allowed identification of 8 patients (all female) with SLE/AAV overlap syndrome and biopsy-proven LN or pauci-immune GN, of whom 3 (patients 2, 6, and 8) had already been reported.9 The characteristics of these patients are summarized in Table 1.
| Patient  | Patient 2 | Patient 3 | Patient 4 |
|----------|-----------|-----------|-----------|
| **Patient 1** | **Patient 2** | **Patient 3** | **Patient 4** |
| **Associated autoimmune disease** | – | Sjögren syndrome | – | Graves–Basedow disease |
| **Time elapsed between the 2 diagnoses** | 2 y | 10 y | 17 y | 5 y |
| **First disease** | SLE | SLE | SLE | AAV |
| **– Age at diagnosis (y)** | 19 | 31 | 38 | 12 |
| **– Clinical manifestations** | Asthenia | Nondestructive polyarthritis | Asthenia/alopecia | Nondestructive polyarthritis |
| | Arthralgia | Raynaud’s phenomenon | Jaccoud’s arthropathy | Skin nodules/livedo |
| **Eccymotic purpura** | Lymphopenia | Malar rash | RPGN (CGN) | |
| **Second disease** | AAV | AAV | AAV | SLE |
| **– Age at diagnosis (y)** | 21 | 41 | 55 | 17 |
| **– Clinical manifestations** | Arthralgia | Nondestructive polyarthritis | Nondestructive polyarthritis | Nondestructive polyarthritis |
| | | | | IAH |
| **Eccymotic purpura** | Bloody rhinitis | IAH | Raynaud’s phenomenon | Lymphopenia |

**Characteristics of the overlap diagnosis**

- **SLEDAI/BVAS**
  - Patient 1: 22/4
  - Patient 2: 16/7
  - Patient 3: 16/7
  - Patient 4: 17/5

- **Renal clinical and biological involvement**
  - Hematuria/leucocyturia
  - Patient 1: Hematuria/leucocyturia
  - Patient 2: RPGN
  - Patient 3: RPGN
  - Patient 4: Proteinuria

- **Clinical tests**
  - Hemoglobin (g/dL)
    - Patient 1: 9.2
    - Patient 2: 7.8
    - Patient 3: 10.5
    - Patient 4: 12.1
  - CRP (mg/L)
    - Patient 1: 2
    - Patient 2: 16
    - Patient 3: 88
    - Patient 4: 50
  - Serum creatinine (mg/dL)
    - Patient 1: 1.02
    - Patient 2: 7.11
    - Patient 3: 5.63
    - Patient 4: 1.01
  - Proteinuria (g/day)
    - Patient 1: 0.8
    - Patient 2: 3.2
    - Patient 3: 3.6
    - Patient 4: 0.3
  - ANA/anti-ENA
    - Patient 1: 1/800, speckled (SSA)
    - Patient 2: 1/1280, speckled (SSA/Sm/RNP)
    - Patient 3: 1/1280, speckled (SSA/Sm/RNP)
    - Patient 4: 1/640, speckled (SSA/Sm/RNP)
  - Anti-dsDNA (UI/mL)
    - Patient 1: 23
    - Patient 2: 9
    - Patient 3: 10
    - Patient 4: 20
  - Low C3/C4
    - Patient 1: –/–
    - Patient 2: –/–
    - Patient 3: –/–
    - Patient 4: –/–
  - ANCA/specificity/titer
    - Patient 1: –/–/–
    - Patient 2: –/–/–
    - Patient 3: –/–/–
    - Patient 4: –/–/–
  - Lupus anticoagulant/ACL/anti-β2-GP-1
    - Patient 1: –/–/–
    - Patient 2: –/–/–
    - Patient 3: –/–/–
    - Patient 4: –/–/–

**Renal pathology**

- **Description**
  - Pauci-immune GN (mixed)
    - Patient 1: 17
    - Patient 2: 10
    - Patient 3: 6
    - Patient 4: 14
  - Pauci-immune GN (sclerotic)
    - Patient 1: 2 + 5 fibrous crescents
    - Patient 2: 8
    - Patient 3: 2
    - Patient 4: 1 + 2 fibrous crescents
  - Crescentic or necrotic glomeruli (n)
    - Patient 1: 0
    - Patient 2: 1
    - Patient 3: 2
    - Patient 4: 0
  - Glomeruli with endocapillary proliferation (n)
    - Patient 1: 0
    - Patient 2: 0
    - Patient 3: 0
    - Patient 4: 0
  - Subepithelial deposits (IgG/IgM/IgA/C3/C1Q)
    - Patient 1: –/–/–/–/–
    - Patient 2: –/–/–/–/–
    - Patient 3: –/–/–/–/–
    - Patient 4: –/–/–/–/–
  - Subendothelial deposits (IgG/IgM/IgA/C3/C1Q)
    - Patient 1: –/–/–/–/–
    - Patient 2: –/–/–/–/–
    - Patient 3: –/–/–/–/–
    - Patient 4: –/–/–/–/–
  - Mesangial deposits (IgG/IgM/IgA/C3/C1Q)
    - Patient 1: –/–/–/–/–
    - Patient 2: –/–/–/–/–
    - Patient 3: –/–/–/–/–
    - Patient 4: –/–/–/–/–
  - Interstitial inflammation
    - Patient 1: Absent
    - Patient 2: Absent
    - Patient 3: Absent
    - Patient 4: Absent
  - Vascular lesions
    - Patient 1: None
    - Patient 2: None
    - Patient 3: None
    - Patient 4: None
| Patient | Age, Sex | First Disease | Second Disease | Characteristics of the Overlap Diagnosis |
|---------|----------|---------------|----------------|------------------------------------------|
| Patient 5 | 41 y, F | CAPS | SLE | Hematuria/leucocyturia |
| Patient 6 | 53 y, F | AAV | AAV | Hematuria/leucocyturia |
| Patient 7 | 27 y, F | SLE | AAV | Hematuria/leucocyturia |
| Patient 8 | 74 y, F | SLE | AAV | Hematuria/leucocyturia |

**Associated autoimmune disease**
- CAPS
- Idiopathic thrombocytic purpura

**Time elapsed between the 2 diagnoses**
- Patient 5: 18 y
- Patient 6: 6 y
- Patient 7: 0
- Patient 8: 0

**First disease**
- AAV
- SLE

**Clinical manifestations**
- Bloody rhinitis / ecchymotic purpura
- Nondestructive polyarthritis
- Myocardial ischemia/skin nodules
- Hemolytic anemia
- Nondestructive polyarthritis
- Thrombopenia
- Cerebral ischemia/IAH

**Second disease**
- SLE
- AAV

**Clinical manifestations**
- Weight loss
- Nondestructive polyarthritis
- Ecchymotic purpura
- Hemolytic anemia
- Cerebral ischemia/IAH

**Characteristics of the overlap diagnosis**
- SLEDAI/BVAS: 24/3
- Renal clinical and biological involvement:
  - RPGN
  - RPGN
  - RPGN
  - RPGN

**Biological tests**
- Hemoglobin (g/dL)
- C-RP (mg/L)
- Serum creatinine (mg/dL)
- Proteinuria (g/day)
- ANAs/anti-ENA
- Anti-dsDNA (UI/mL)
- Low C3/C4
- ANCA/specificity/titer
- Lupus anticoagulant/
  - ACL/anti-β2GP1

**Renal pathology**
- Description:
  - Class IV-G LN: Pauci-immune GN (crescentic/ focal)
  - Class IV-G LN

**Glomeruli (n)**
- 16
- 7
- 38
- 17

**Sclerotic glomeruli (n)**
- 7
- 0
- 0
- 9

**Crescentic or necrotic glomeruli (n)**
- 3
- 7
- 10
- 3

**Glomeruli with endocapillary proliferation (n)**
- 9
- 0
- 0
- 8

**Subepithelial deposits (IgG/IgM/IgA/C3/C1Q)**
- /–/–/–
- /–/–/–
- /–/–/–
- /–/–/–

**Subendothelial deposits (IgG/IgM/IgA/C3/C1Q)**
- 2+/+/3+/3+/2+
- /–/–/–
- /–/–/–
- /–/–/2+/–

**Mesangial deposits (IgG/IgM/IgA/C3/C1Q)**
- /–/–/–
- /–/–/–
- +/±/+/
- 2+/–/2+/–
SLE was the inaugural disease in 3 patients, whereas AAV was first diagnosed in 3 others, and SLE and AAV occurred concomitantly in 2 patients. Median age at the time when overlap syndrome was diagnosed was 40 years (range 17–74).

SLE manifestations were articular (8/8), hematological (6/8), and mucocutaneous (6/8). AAV manifestations included articular (7/8), mucocutaneous (4/8), pulmonary (4/8), and ear–nose–throat (3/8) involvement. Myocardial ischemia, cerebral infarction, and episceralitis were all reported in 1 patient. One patient (patient 3) presented with intra-alveolar hemorrhage (IAH) and cerebral infarction. One patient (patient 6) had a past history of nephritic syndrome due to class V LN, 17 years before the occurrence of rapidly progressive GN with IAH, which led to a diagnosis of MPO-associated AAV with pauci-immune GN. Four patients had a past history of another autoimmune disease that consisted of Sjögren’s syndrome, Graves–Basedow disease, idiopathic thrombocytopenic purpura, and/or antiphospholipid syndrome.

At the time when overlap syndrome was diagnosed, median SLEDAI score was 17 (range: 14–26) and median BVAS was 6 (range: 3–9). The most frequent presentation was rapidly progressive GN (6/8 cases), with IAH in 3 patients. Median serum creatinine was 2.47 mg/dL (range: 1.01–7.11). All patients had positive ANA, 5/8 had anti-dsDNA, and 7/8 patients had anti-MPO antibodies.

Pathological diagnosis was pauci-immune GN in 5/8 patients (crescentic; focal; sclerotic, respectively, in 1 case and mixed in 2 cases); it was LN for the other 3 cases (class IV-G in 2 cases, both with crescents, and class II with fibrous crescents in 1 case). The pathological results are provided in Table 1. Some cases of LN showed prominent crescentic glomeruli, with mild endocapillary proliferation and little immune deposition, whereas some cases of pauci-immune GN showed moderate mesangial immunoglobulin deposition and proliferation. An induction immunosuppressive regimen for the overlap syndrome included corticosteroids and cyclophosphamide in 7/8 patients, associated with plasma exchanges in 3/8 patients. All patients received a maintenance treatment that included steroids. The detailed therapeutic regimens for each patient are shown in Table 2. Median follow-up after treatment of overlap syndrome was 2 (range: 2–21) years. During the follow-up, 1 patient died from hepatocellular carcinoma at M7, remission was obtained in 4 patients, and 3 patients developed chronic kidney disease (stage 3 for 2 patients, stage 5 requiring hemodialysis and kidney transplantation for 1 patient). A relapse of AAV occurred in 2 patients after 4 and 5 years. Serious infectious adverse events occurred in 2 other patients (1 bacterial pneumonia and 1 infectious endocarditis).

### Systematic Literature Review

A systematic literature review allowed the identification of 31 additional cases of SLE/AAV overlap syndrome with renal involvement (excluding the 3 French patients included in the present cohort), among which 30 were documented by a renal biopsy. Their characteristics are described in Table 3 and compared with those of the 8 patients from the present study. Consistent with our study, patients were mostly female and presented with rapidly progressive GN (30/31). P-ANCA antibodies were detected in 30/31, anti-MPO antibodies in 21/26 patients, whereas no patient had anti-PR3 antibodies. The mean time interval between the 2 diseases was shorter in the literature than in our patients, with more frequent concomitant diagnoses. Likewise, treatment of overlap syndrome comprised corticosteroids and immunosuppressive drugs.

Overall, in the 39 cases, remission was achieved in 76% (22/29); 4 patients died of infectious adverse events and 1 of cancer (hepatocellular carcinoma). Considering patients for whom a previous treatment was reported, 5/27 (including patient 7) had received drugs potentially associated with drug-induced SLE or vasculitis (hydralazine n = 3, thioridazine n = 1, etanercept n = 1), among which 3 cases had positive antithistone antibodies.

### Prevalence of Overlapping Auto-Antibodies and of SLE/AAV Overlap Syndrome

Among a cohort registry of consecutive kidney biopsies corresponding to LN and pauci-immune GN, complete immunological data were available for 110 biopsies from 101 patients. There were 44 LN (40%) in 40 patients and 66 cases of pauci-immune GN (60%) in 61 patients; the characteristics are described in Table 4.

Serum ANCA antibodies were detected by IIF at the time of a kidney biopsy in 12 (30%) patients with LN. Fluorescence was perinuclear (p-ANCA) in 9 patients and cytoplasmic (c-ANCA) in 3. Anti-MPO and anti-PR3 antibodies were detected by ELISA in, respectively, 3 and 2 patients.

Kidney biopsies of LN were found in 2 groups according to ANCA IIF positivity. The pathological characteristics are summarized in Table 5. There was no significant clinical or pathological difference in SLE patients according to the presence or absence of ANCA. No patient with LN and positive ANCA fulfilled the AAV classification criteria.

Serum ANA was detected at the time of a renal biopsy in 36 (52%) cases of pauci-immune GN, with a mean titer of 1/700. Fluorescence was speckled in 89% and homogenous in 11% of cases. Antithrombotic nuclear-antigen antibodies were positive in 3 cases (9%), including anti-SSA/SSB in 2 cases and anti-Sm in 1 case. Anti-dsDNA antibodies were positive in 1 patient and were at the threshold positivity value in 7 patients (11%). Low complement fractions were reported in 2 cases (3%). Kidney biopsies of pauci-immune GN were displayed in 2 groups according to serum ANA positivity. The pathological characteristics are summarized in Table 6. There was no significant clinical or pathological
| Patients | Simultaneous Diagnosis | Second Diagnosis | First Disease Treatment | Induction Regimen | Remission M6 | Maintenance Regimen M12 | M18 | M24 | Follow-Up | Relapse | Damage |
|----------|------------------------|------------------|-------------------------|-------------------|-------------|-------------------------|-----|-----|-----------|---------|--------|
| 1        | No                     | AAV              | HCQ                     | CS\(^{+}\)/AZA    | Remission (AAV) | Remission (AAV)          |     |     | 3 y       | –       | –      |
| 2        | No                     | AAV              | HCQ/CS\(^{+}\)          | CS\(^{+}\)/CYC    | Response (AAV)  | Remission (AAV)          |     |     | 2 yr      | –       | Dialysis |
| 3        | No                     | AAV              | HCQ/CS\(^{+}\)          | CS\(^{+}\)/CYC    | Response (AAV)  | Remission (AAV)          |     |     | 21 y      | –       | –      |
| 4        | No                     | SLE              | CS\(^{+}\)/CYC          | CS\(^{+}\)/CYC    | CR (SLE)     | CR (SLE)               | CR (SLE) | 7 y | AAVx1 M48 | –       | –      |
| 5        | No                     | SLE              | CS\(^{+}\)/CYC          | CS\(^{+}\)/CYC    | PR (SLE)     | PR (SLE)               | PR (SLE) | 2 y | – – –     | –       | –      |
| 6        | No                     | SLE              | CS\(^{+}\)/CYC          | CS\(^{+}\)/CYC    | CS\(^{+}\)/MMF | CR (SLE)               | CR (SLE) | 6 y | AAVx1 Stage |
| 7        | Yes                    | Relapse of AAV   | SLE/AAV                  | –                 | CS\(^{+}\)/CYC | Remission (AAV)          |     |     | 2 y       | –       | –      |
| 8        | Yes                    | SLE/AAV          | –                       | CS\(^{+}\)/CYC    | Response (AAV) | AAZA/HCQ               |     |     | 7 months | –       | –      |

AAV: ANCA-associated vasculitis; AZA: azathioprine; CR: complete remission; CKD: chronic kidney disease, CS\(^{+}\): corticosteroids (1 mg/kg/day); CS: corticosteroids (<20 mg/day); CYC: cyclophosphamide; HCQ: hydroxychloroquine; MMF: mycophenolate mofetil; PE: plasma exchange; PR: partial remission; RTX: rituximab; SLE: Systemic lupus erythematosus.
difference in patients with pauci-immune GN according to the presence or absence of ANA.

Among patients diagnosed with pauci-immune GN, only 2 female patients fulfilled the ACR classification criteria for SLE and were included in the national survey cohort for SLE/AAV overlap syndrome (patients 1 and 7). The first patient (1) had scarred pauci-immune GN without active lesions. The second patient (7) presented with unexpected mesangial immune-complex deposits (IgG, IgM, C3, C1q) on a kidney biopsy, with 26% necrotic/crescentic glomeruli and no endocapillary or mesangial proliferation (Figure 1). Both had an inflammatory interstitial infiltrate. Their clinical and biological characteristics are described in Table 1.

Overall, among the 101 patients from this cohort, 57 (56.5%) had typical LN or typical pauci-immune GN, without overlapping antibodies; 12 (12%) had typical LN and positive ANCA antibodies; 30 (29.5%) had typical pauci-immune GN and positive ANA antibodies; and only 2 (2%) patients fulfilled the classification criteria for both SLE and AAV, corresponding to the SLE/AAV overlap syndrome.

**DISCUSSION**

Combining the results from a national survey across referral centers and a systematic literature review, we report here on what is, to the best of our knowledge, the largest series

---

**TABLE 3. Patients With the SLE/AAV Syndrome From the Present Report and From Previous Reports in the Literature**

|                        | Present Report n = 8 | Literature Review n = 31 | Total n = 39 |
|------------------------|----------------------|--------------------------|--------------|
| **General characteristics** |                      |                          |              |
| Sex ratio n, (F/M)     | 8 (8/0)              | 21 (18/3)                | 90%/10%      |
| Associated autoimmune disease | 4/8                  | 1/19                     | 19%          |
| Mean age at diagnosis of SLE (y ± SD) | 36 ± 18              | 45 ± 20                  | 40 ± 20      |
| Mean age at diagnosis of AAV (y ± SD) | 36 ± 20              | 48 ± 21                  | 42 ± 21      |
| Simultaneous diagnosis | 2/8                  | 25/31                    | 69%          |
| First disease SLE      | 3/6                  | 6/6                      | 75%          |
| Time elapsed between the 2 diagnoses (y, mean ± SD) | 7 ± 7                | 2 ± 7                    | 4.5 ± 7      |
| **Manifestations of SLE:** |                      |                          |              |
| Cutaneous              | 6/8                  | 6/20                     | 43%          |
| Articular              | 8/8                  | 7/20                     | 54%          |
| Pulmonary              | 1/8                  | 6/21                     | 24%          |
| Neurologic             | 1/8                  | 4/20                     | 18%          |
| **Manifestations of AAV:** |                      |                          |              |
| Cutaneous              | 4/8                  | 1/20                     | 18%          |
| Articular              | 7/8                  | 4/20                     | 39%          |
| ENT                    | 3/8                  | 2/20                     | 18%          |
| Pulmonary              | 4/8                  | 5/21                     | 31%          |
| Neurologic             | 1/8                  | 1/20                     | 7%           |
| **Renal presentation of SLE/AAV overlap** |                      |                          |              |
| RPGN                   | 6/8                  | 30/31                    | 92%          |
| Nephrotic syndrome     | 0/8                  | 1/31                     | 2.5%         |
| Proteinuria and hematuria | 2/8                  | 0/31                     | 5%           |
| **Overlap biology**    |                      |                          |              |
| ANCA (IIF)             | 7/8                  | 30/31                    | 95%          |
| Anti-MPO (ELISA)       | 7/8                  | 21/26                    | 82%          |
| Anti-PR3 (ELISA)       | 0/8                  | 0/26                     | 0%           |
| AAN +                  | 8/8                  | 20/20                    | 100%         |
| Anti-dsDNA (Farr test > n) | 5/8                  | 9/20                     | 50%          |
| Low C3/C4              | 4/8                  | 14/18                    | 69%          |
| **Renal pathology**    |                      |                          |              |
| % crescentic/ necrosis glomeruli (mean ± SD) | 37 ± 35              | 42 ± 28                  | 40 ± 31      |
| Presence of endocapillary proliferation | 1/8                  | 6/18                     | 27%          |
| Presence of subepithelial deposits | 0/8                  | 12/16                    | 50%          |
| Presence of subendothelial deposits | 3/8                  | 0/17                     | 12%          |
| Presence of mesangial deposits | 4/8                  | 16/17                    | 80%          |
| Presence of interstitial inflammation | 2/8                  | 16/16                    | 75%          |
| **Treatment**          |                      |                          |              |
| Corticosteroids        | 7/8                  | 31/31                    | 97%          |
| Cyclophosphamide       | 7/8                  | 20/21                    | 93%          |
| Response               | 7/8                  | 15/21                    | 76%          |

AAV = ANCA-associated vasculitis, ENT = ear, nose and throat, RPGN = rapidly progressive glomerulonephritis, SLE = systemic lupus erythematosus.
of patients with histologically proven GN and SLE/AAV overlap syndrome.

SLE and AAV are rare autoimmune diseases that share clinical symptoms, such as arthritis and cutaneous lesions, as well as possibly severe renal involvement. Whereas SLE and AAV can be easily distinguished by demographic characteristics, an autoantibody profile and a renal pathology in most cases, some patients display mixed patterns responding to both SLE and AAV classification criteria. Altogether, patients with SLE/AAV overlap syndrome are mostly female, with a wide range of age distributions at the onset of SLE or AAV. The presentation of AAV is MPA-like in most patients, with articular, cutaneous and renal involvement, as well as IAH in some patients, concordant with the exclusive positivity of anti-MPO antibodies. Although ear–nose–throat involvement was present in some patients, no granuloma has been documented on renal pathology, and no patient with SLE/AAV overlap from our study or the literature had anti-PR3 antibodies. Renal pathology, classified as either LN or pauci-immune GN according to the predominant type of lesion, displayed overlapping lesions in some cases.

Crescentic GN is not rare in SLE: it accounts for 10% of biopsy-proven LN and 20% of class IV-G LN. The presence of ANCA antibodies has been reported in up to 20% of SLE patients in the literature, but their prevalence varies between IIF and ELISA. Interestingly, anti-MPO ANCA antibodies are more frequently encountered in patients with crescentic LN than in patients with noncrescentic LN. Some authors also report a correlation between p-ANCA and crescent formation and a possible association between other p-ANCA, namely anticathepsin G antibodies and the development of LN, suggesting a potential pathogenic role for p-ANCA in crescent formation.

The ISN/RPS 2003 classification of LN individualizes segmental from a global pattern of class IV LN, suggesting that they may have a different pathogenesis and prognosis. An association of segmental forms of proliferative LN with crescents and necrosis has been reported by several authors, whereas global patterns are associated with abundant immune-complex deposits. Although some segmental forms of proliferative LN are considered similar to pauci-immune GN, ANCA status is not available for most patients in these cohorts.

Likewise, although ANCA-associated GN is defined as pauci-immune, the presence of immune-complex deposits has been documented by electron microscopy in 18 and 54% of patients from 2 large cohorts, without mention of ANA status.

We assessed the prevalence of overlapping antibodies and their association with renal pathological features in a cohort of biopsy-proven GN. The prevalence of ANCA in LN cohorts is consistent with data from the literature, with less common MPO or PR3 specificity. We describe, for the first time, a high prevalence of ANA in patients with pauci-immune GN. However, the presence of overlapping antibodies in LN or pauci-immune GN was not associated with the proportion of crescentic glomeruli, or the presence of endocapillary proliferation, interstitial inflammation, or immune deposits in this cohort. Finally, we do not find a pathological relevance for overlapping antibodies, which highlights the difference between true SLE/AAV overlap syndrome and the more common finding of ANCA positivity in LN.

This study has some limitations. The absence of electron microscopy of kidney biopsies prevented detailed analysis of localization of immune-complex deposits. Also, SLE/AAV overlap syndrome may have been underestimated in this study due to the small number of cases. Indeed, because of the stringent inclusion criteria, with exclusion of patients with exclusively extra-renal manifestations of SLE and AAV, only 8 patients with biopsy-proven GN were identified after screening a large database that included 3300 cases of vasculitis, of which 1990 were AAV from the FSGV registry.

Although this study was not designed to address the pathophysiology of SLE/AAV overlap syndrome, some hypotheses can be made. First, the co-occurrence of SLE and AAV may be part of a global poly-autoimmunity in some patients, as suggested by the frequent association with a third autoimmune disease in our cohort. The shift and diversification of autoantibody targets during the course of autoimmune diseases has been

TABLE 4. Characteristics of Patients With Lupus Nephritis (LN) and Pauci-Immune Glomerulonephritis (GN) From an Independent Cohort (110 Renal Biopsies Performed in 101 Patients)

|                        | LN                                    | Pauci-Immune GN |
|------------------------|---------------------------------------|-----------------|
| Number of biopsies (%) | 44 (40)                               | 66 (60)         |
| Number of patients (%) | 40 (40)                               | 61 (60)         |
| Gender M/F (%)         | 10/30 (25/75)                         | 27/34 (44/56)   |
| Mean age, years, ± SD (range) | 33 ± 17 (8–76)  | 62 ± 16 (14–89) |
| Specific pathological class, n (%) |                       |                 |
| LN II                   | 4 (9)                                 | 19 (29)         |
| LN III                  | 6 (13.5)                              | 31 (47)         |
| LN IV                   | 21 (48)                               | 8 (12)          |
| LN V                    | 3 (7)                                 | 8 (12)          |
| LN III + V              | 2 (4.5)                               |                 |
| LN IV + V               | 8 (18)                                |                 |
| ANA, n patients (%)     | 40 (100)                              | 32 (52)         |
| Anti-dsDNA, n patients (%) | 39 (97.5)                            | 1 (2)           |
| ANCA IIF, n patients (%) | 12 (30)                              | 53 (87)         |
| Anti-MPO (%)            | 3/12 (25)                             | 26/53 (49)      |
| Anti-PR3 (%)            | 2/12 (16)                             | 25/53 (47)      |

GN = glomerulonephritis, LN = lupus nephritis.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
defined as epitope spreading.34 This phenomenon has been studied in SLE, in particular, and may explain the numerous autoantibodies encountered in SLE and the frequent association of SLE with antiphospholipid syndrome or Sjögren’s syndrome.1,35 It has been also studied in AAV, where the spread of the ANCA epitope may differentiate patients with full-blown vasculitis from patients with positive antibodies but with no clinical manifestations.36 The association of AAV with another autoimmune disease, although rare, has been reported.37,38

The second hypothesis is that drug exposure may have participated in some patients. The presence of anti-MPO antibodies has already been reported in patients with drug-induced SLE.39 In the literature, 4 cases of SLE/AAV overlap syndrome had been exposed to hydralazine or thioridazine, which have been associated with drug-induced SLE or AAV.39–41 One additional patient from the present report had received etanercept, a drug associated with SLE autoantibody generation and sometimes clinical symptoms of SLE.40 The shared genetic

### TABLE 5. Clinical and Pathological Characteristics of Patients With Lupus Nephritis (LN) According to ANCA Status

|                         | Total | SLE ANCA− | SLE ANCA+ | P Value |
|-------------------------|-------|-----------|-----------|---------|
| Clinical data           |       |           |           |         |
| Number of patients      | n = 40| 28        | 12        |         |
| Gender (M/F)            | 8/20  | 2/10      |           |         |
| Age, y (mean ± SD)      | 32 ± 16| 36 ± 18  | 0.18      |         |
| Pathological data       |       |           |           |         |
| Number of biopsies      | n = 44| 32        | 12        |         |
| Sclerotic glomeruli, % mean ± SD | 14 ± 18 | 6 ± 12  | 0.28      |         |
| Cellular crescents or necrosis, % mean ± SD | 12 ± 19 | 9 ± 15  | 0.44      |         |
| Presence of endocapillary proliferation, n (%) | 21 (66) | 8 (67)  | 0.89      |         |
| Presence of interstitial inflammation, n (%) | 18 (56) | 6 (50)  | 0.69      |         |
| Presence of subendothelial deposits, n (%) | 18 (56) | 8 (67)  | 0.16      |         |
| IgG, n (%)              | 14 (72) | 13 (72)  | 8 (100)   |         |
| C3, n (%)               | 15 (83) | 12 (67)  | 8 (100)   |         |
| C1Q, n (%)              | 6 (58)  | 7 (58)  |           |         |
| Presence of mesangial deposits, n (%) | 6 (19)  | 7 (58)  | 0.1       |         |
| IgG, n (%)              | 5/6 (83) | 6/6 (100)| 7 (100)   |         |
| C3, n (%)               | 6/6 (100)| 6/6 (100)| 7 (100)   |         |
| C1Q, n (%)              | 4/6 (67)| 4/6 (67)| 7 (100)   |         |

ANCA = antineutrophil cytoplasmic antibodies, LN = lupus nephritis, SD = standard deviation, SLE = systemic lupus erythematosus.

### TABLE 6. Clinical and Pathological Characteristics of Patients With Pauci-Immune Glomerulonephritis (GN) According to ANA Status

|                         | Total | Pauci-immune GN ANA− | Pauci-immune GN ANA+ | P Value |
|-------------------------|-------|-----------------------|-----------------------|---------|
| Clinical data           |       |                       |                       |         |
| Number of patients      | n = 61| 29                    | 32                    |         |
| Gender (M/F)            | 14/15 | 13/19                 |                       |         |
| Age, y (mean ± SD)      | 63 ± 16| 60 ± 17  | 0.25                 |         |
| Pathological data       |       |                       |                       |         |
| Number of biopsies      | n = 66| 30                    | 36                    |         |
| Sclerotic glomeruli, % mean ± SD | 22 ± 22 | 20 ± 20  | 0.43                 |         |
| Cellular crescents/necrosis, % mean ± SD | 41 ± 38 | 44 ± 46  | 0.38                 |         |
| Presence of endocapillary proliferation, n (%) | 0 (0)  | 0 (0)  |                       |         |
| Presence of interstitial inflammation, n (%) | 21 (70) | 20 (56)  | 0.41                 |         |
| Presence of subendothelial deposits, n (%) | 4 (13) | 6 (17)  | 0.16                 |         |
| IgG, n (%)              | 0 (0)  | 0 (0)                 |                       |         |
| C3, n (%)               | 4 (100) | 6 (100)  |                       |         |
| C1Q, n (%)              | 0/10  | 0 (0)                 |                       |         |
| Presence of mesangial deposits (mean ± SD, %) | 1 (3)  | 6 (17)  | 0.1                  |         |
| IgG, n (%)              | 0 (0)  | 2 (33)                |                       |         |
| C3, n (%)               | 1 (100) | 6 (100)  |                       |         |
| C1Q, n (%)              | 0 (0)  | 1 (17)                |                       |         |

ANA = antinuclear antibodies, GN = glomerulonephritis.
variants, identified through genome-wide association studies, may predispose patients to the development of several immune-mediated disease. Finally, although neutrophil activation is the hallmark of AAV, gene-expression studies have shown a strong neutrophil signature in SLE. The release of neutrophil extracellular traps in particular, may participate in the pathogenesis of both AAV-related GN and lupus nephritis.

**CONCLUSION**

The association of SLE and AAV with biopsy-proven GN seems rare, but not fortuitous. Patients with SLE/AAV overlap syndrome are mostly female, present with a severe clinical presentation (rapidly progressive GN and frequent pulmonary involvement), and have both ANA and anti-MPO antibodies. Future studies are needed to investigate the possible shared immune pathogenesis that may facilitate the co-occurrence of SLE and AAV in these patients and so lead to new therapeutic options.

**ACKNOWLEDGMENTS**

The authors thank the “Amicale des Jeunes Internistes” (AJI) for their help with this study.

**REFERENCES**

1. D'Cruz DP, Khamashata MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369:587–596.
2. Cervera R, Khamashata MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82:299–308.
3. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346:319–323.
4. Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine. 2006;85:95–104.
5. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
6. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628–1636.
7. Naer SH, D'Agati VD, Park HR, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol. 2008;3:682–690.
8. Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol. 2000;20:57–63.
9. Hervier B, Hamidou M, Haroche J, et al. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int. 2012;32:3285–3290.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
11. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.
12. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–640.
13. Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827–1832.
14. Arahata H, Migna K, Izumoto H, et al. Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clin Rheumatol. 1999:18:77–81.
15. Cavagna L, Caporalii R, Esposito C, et al. Clinical features of ANCA-positive systemic lupus erythematosus: report of two cases. Scand J Rheumatol. 2007;36:74–76.
16. Chang A, Anekliokoro O, Meehan SM, et al. Membranous and crescentic glomerulonephritis in a patient with anti-nuclear and anti-neutrophil cytoplasmic antibodies. Kidney Int. 2007;71:360–365.
17. Erdogan O, Oner A, Demircin G, et al. A boy with consecutive development of SLE and Wegener granulomatosis. Pediatr Nephrol. 2004;19:438–441.
18. Hirai Y, Iyoda M, Shihata T, et al. Lupus nephritis associated with positive MPO-ANCA in a patient with underlying autoimmune hemolytic anemia. Clin Exp Nephrol. 2008;12:393–397.
19. Isono M, Araki H, Hatai T, et al. Diffuse alveolar hemorrhage in lupus nephritis complicated by microscopic polyangiitis. Clin Exp Nephrol. 2011;15:294–298.
20. Kobayashi S, Inokuma S. Intrapulmonary hemorrhage in collagen-vascular diseases includes a spectrum of underlying conditions. Intern Med. 2009;48:891–897.
21. Koenig KF, Kalbermatter SA, Menter T, et al. Rapidly progressive lupus nephritis with extremely high levels of antineutrophil cytoplasmic antibodies. Case Rep Nephrol Urol. 2014;4:5–11.
22. Sangala N, Lee RW, Horsfield C, et al. Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe. Int Urol Nephrol. 2010;42:503–506.
23. Yu F, Tan Y, Liu G, et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76:307–317.
24. Villiger PM, Guillein L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev. 2010;9:812–819.
25. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12:651–658.
26. Galeazzi M, Morozzi G, Sebastiani GD, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998;16:541–546.
27. Lee SS, Lawton JW, Chan CE, et al. Antilactoferrin antibody in systemic lupus erythematosus. Br J Rheumatol. 1992;31:669–673.
28. Lee SS, Lawton JW, Chak W. Distinction between antinuclear antibody and P-ANCA. J Clin Pathol. 1991;44:962–963.
29. Hill GS, Delahousse M, Nochy D, et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005;68:2288–2297.
30. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156–2163.
31. Schwartz MM, Roberts JL, Lewis EJ. Necrotizing glomerulitis of systemic lupus erythematosus. Hum Pathol. 1983;14:158–167.
32. Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65:2145–2152.
33. Neumann I, Regele H, Kain R, et al. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant. 2003;18:524–531.
34. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2:85–95.
35. Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246–255.
36. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123:1773–1783.
37. Guellle D, Gall EC, Groh M, et al. ANCA-associated vasculitis in patients with primary Sjögren’s syndrome: detailed analysis of 7 new cases and systematic literature review. Autoimmun Rev. 2015;14:742–750.
38. Quemeneur T, Mouthon L, Cacoub P, et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine. 2013;92:1–9.
39. Cambridge G, Wallace H, Bernstein RM, et al. Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol. 1994;33:109–114.
40. De Rycke L, Baeten D, Kruihof E, et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14:931–937.
41. Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19:338–347.
42. Zhernakova A, van Diemen CC, Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet. 2009;10:43–55.
43. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10:463–473.
44. Bennett L, Palucha AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197:711–723.
45. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66:1583–1595.
46. Nakou M, Knowlton N, Frank MB, et al. Gene expression in systemic lupus erythematosus: bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. Arthritis Rheumatol. 2008;58:3541–3549.
47. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–1535.
48. Kessenbrock K, Krumholz M, Schonermann U, et al. Netting neutrophils in autoimmune small-vascular vasculitis. Nat Med. 2009;15:623–625.
49. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187:538–552.